Abstract
Aims Impaired awareness of hypoglycemia (IAH) is a limiting factor in the treatment of type 1 diabetes (T1D) and is a challenging condition to reverse. The objective of this study was to test the hypothesis that naltrexone therapy in subjects with T1D and IAH will improve counterregulatory hormone response and recognition of hypoglycemia symptoms during hypoglycemia. Methods We performed a pilot randomized double blind trial of 4 weeks of naltrexone therapy (n = 10) or placebo (n = 12) given orally in subjects with T1D and IAH. Outcome measures included hypoglycemia symptom scores, counterregulatory hormone levels and thalamic activation as measured by cerebral blood flow using MRI during experimental hypoglycemia in all subjects before and after 4 weeks of intervention. Results After 4 weeks of therapy with naltrexone or placebo, no significant differences in response to hypoglycemia were seen in any outcomes of interest within each group. Conclusions In this small study, short-term treatment with naltrexone did not improve recognition of hypoglycemia symptoms or counterregulatory hormone response during experimental hypoglycemia in subjects with T1D and IAH. Whether this lack of effect is related to the small sample size or due to the dose, the advanced stage of study population or the drug itself should be the subject of future investigation.
Original language | English (US) |
---|---|
Pages (from-to) | 1277-1282 |
Number of pages | 6 |
Journal | Journal of Diabetes and Its Complications |
Volume | 29 |
Issue number | 8 |
DOIs | |
State | Published - Nov 2015 |
Bibliographical note
Publisher Copyright:© 2015 Elsevier Inc. All rights reserved.
Keywords
- HAAF
- Hypoglycemia
- Impaired awareness of hypoglycemia
- Naltrexone
- Opioid antagonists
- Type 1 diabetes